## INDEX TO AUTHORS: LABORATORY MANAGEMENT, 1983

Abramson, C.: The Serodiagnostic Aspects of S. aureus Infections, Nov., 48

Adkinson, M.F. and Hamilton, R.G.: Clinical Laboratory Methods in Allergic Disease,

Dec., 37 Arii, D. and Terasaki, P.I.: The HLA Antigens: Histocompatbility Testing Methods for Kidney Transplantation, Sept., 33

### B

Bakerman, S.: Fluorescence Polarization Immunoassay, Chem Cues, July, 16 Metal Poisoning: The Laboratory Detection of Lead, Arsenic, and Mercury, Chem Cues, April, 13 Substrate-Labeled Fluorescence Immunoassay, Chem

Cues, Oct., 13 Bakerman, S. and Khazanie, P.G.: Toxicologic Testing for Common Drugs, Chem Cues, Jan., 11

Ban, Y. and Murphy, G.P.: Antigen Marker Assays in Prostate Cancer, April, 19

Bates, H.M.: Estriol Assays in Monitoring Fetal/Placental Function, Laboratory Pathfinder, Feb., 17

The Glycemic Index, Laboratory Pathfinder, Sept., 27 Insulinoma and Pheochromocytoma, Laboratory Pathfinder, May, 11

Microcytosis, Laboratory Pathfinder, Dec., 13

Pulmonary Embolism: The Status of Laboratory Diagnostic Methods, Laboratory Pathfinder, Aug., 17 Baylin, S. and Mendelsohn, G.:

Medullary Thyroid Carcinoma: Diagnostic and Clinical Features, Aug., 21

Bienvenu, F., Bienvenu, J., Sann, L., and Killingsworth, L.M.: The Acute-Phase Proteins in Neonatal Infection. Oct., 47

Bienvenu, J., Bienvenu, F., Sann, L., and Killingsworth, L.M.: The Acute-Phase Proteins in Neonatal Infection, Oct., 47

Block, M., Politis, C., and Karamerou, A.: Pathophysiologic Aspects of the Bone/Marrow/ Fat Relationship, Feb., 40

Blumberg, B.S.: Introduction: The Clinical Laboratory Diagnosis of Viral Hepatitis, Jan.,

Monitoring: The Hidden Factors, June, 29

Brown, W.V. and Gibson, J.C.: The Human Plasma Apolipoproteins: Assay Methods. Part I, March, 19 Part II, April, 27

### ם

Davis, J.M., Jones, F.D., Shaughnessy, R., and Maas, J.: MHPG Excretion and Red-Cell Lithium Transport in Diagnostic Psychiatry, May, 17

DeLand, F.H. and Goldenberg, D.M.: Radioimmunodetection: An In Vivo Tumor Detection System, July, 19

Dosik, H. and Verma, R.S.: Chromosome Banding: Techniques and Prospects, March,

mic Drugs: A Comparison of Therapeutic Monitoring Methods, Dec., 51

Eckfeldt, J.H. and Leiendecker-Foster, C.: a,-Antitrypsin Deficiency: An Automated Screening Method, Aug., 36

Fabisinski, L.F., III and Pribor, H.C.: Artificial Intelligence in Laboratory Medicine. Part III: The Parathyroid Hormone Profile, Clinical Forum, June,

Fabisinski, L.F., III, Scarry, R.L., Green, W.F., and Pribor, H.C.: Artificial Intelligence in Laboratory Medicine. Part IV: The Immunocompetence Profile, Clinical Forum, Dec., 27

Friedman, H., Klein, T., and Widen, R.: Newer Immunoassays in Clinical Bacteriology, Nov., 37

Friedman, H. and Specter, S .: Introduction: The Immunoserologic Diagnosis of Bacteri-

al Infection, Nov., 13 Friedman, H., Widen, R., and Klein, T.: Immunodiagnostic Assays for Legionellosis, Nov., 19

## G

Garry, P.J.: Vitamin C: Metabolic and Laboratory Aspects, May. 31

Boeckx, R.L.: Therapeutic Drug Gibson, J.C. and Brown, W.V.: London, W.T. and Micozzi, M.S.: The Human Plasma Apolipoproteins: Assay Methods. Part I, March, 19 Part II, April, 27

Gilardi, G.L.: Pseudomonas cepacia: Culture and Laboratory Identification, Jan., 29

Goldenberg, D.M. and DeLand, F.H.: Radioimmunodetection: An In Vivo Tumor Detection System, July, 19

Green, W.F., Scarry, R.L., Fabisinski, L.F., III, and Pribor, H.C.: Artificial Intelligence in Laboratory Medicine. Part IV: The Immunocompetence Profile, Clinical Forum, Dec., 27

Gruber, H.E. and Seegmiller, J.E.: The Clinical and Laboratory Significance of Uric Acid Assay, Oct., 21

Drayer, D.E.: The Antiarrhyth- Hamilton, R.G. and Adkinson, M.F.: Clinical Laboratory Methods in Allergic Disease, Dec., 37

Jones, F.D., Shaughnessy, R., Davis, J.M., and Maas, J.: MHPG Excretion and Red-Cell Lithium Transport in Diagnostic Psychiatry, May, 17

Karamerou, A., Politis, C., and Block, M.: Pathophysiologic Aspects of the Bone/Marrow/ Fat Relationship, Feb., 40

Khazanie, P.G. and Bakerman, S.: Toxicologic Testing for Common Drugs, Chem Cues, Jan., 11

Killingsworth, L.M., Bienvenu, J., Bienvenu, F., and Sann, L.: The Acute-Phase Proteins in Neonatal Infection, Oct., 47

Klein, T., Friedman, H., and Widen, R.: Immunodiagnostic Assays for Legionellosis, Nov., 19

Klein, T., Widen, R., and Friedman, H.: Newer Immunoassays in Clinical Bacteriology, Nov., 37

Larsson, L. and Mardh, P.-A.: Gas Chromatography/Mass Spectrometry: Prospects in Clinical Microbiology, April,

Leindecker-Foster, C. and Eckfeldt, J.H.: a,-Antitrypsin Deficiency: An Automated Screening Method, Aug., 36

The Clinical Laboratory Diagnosis of Viral Hepatitis, Jan.,

Lott, J.A.: Electrophoretic CK and LD isoenzyme Assays in Myocardial Infarction, Feb.,

Lum, G.: The Differential Diagnosis of Hypercalcemic Disease, March, 29

Maas, J., Jones, F.D., Shaugh-nessy, R., and David, J.M.: MHPG Excretion and Red-Cell Lithium Transport in Diagnostic Psychiatry, May, 17

Mardh, P. A. and Larsson, L.: Gas Chromatography/Mass Spectrometry: Prospects in Clinical Microbiology, April,

Mendelsohn, G. and Baylin, S.B.: Medullary Thyroid Carcinoma: Diagnostic and Clinical Features, Aug., 21

Micozzi, M.S., and London, W.T.: The Clinical Laboratory Diagnosis of Viral Hepatitis, Jan.,

Murphy, G.P. and Ban, Y.: Antigen Marker Assavs in Prostate Cancer, April, 19

Noel, S.I. and Pribor, H. (ed.): Immunochemical Assays for LD-1 and CK: an Evaluation, Clinical Forum, March, 15

Philip, A.: The Exoantigen Test: A Rapid Identification Method for Dimorphic Fungi, July,

Pifer L.L.: Rapid Assays for Pediatric Infectious Disease, Feb., 35

Pindyck, J. and Waldman, A.A.: Blood Donor Alanine Aminotransferase Levels: An Automated Screening System. June, 53

Polin, R.A. and Wasserman, R.L.: Monoclonal Antibodies: Progress and Promise, Oct., 33 Politis, C., Karamerou, A., and Block, M.: Pathophysiologic Aspects of the Bone/Marrow/

Fat Relationship, Feb., 40 Pribor, H.C. and Fabisinski, L.F., III: Artificial Intelligence in Laboratory Medicine. Part III: The Parathyroid Hormone

## INDEX TO AUTHORS: LABORATORY MANAGEMENT, 1983

Profile, Clinical Forum, June,

Pribor, H.C., (ed.) and Noel, S.I.: immunochemical Assays for LD-1 and CK: An Evaluation, Clinical Forum, March, 15

Pribor, H.C., Scarry, R.L., Green, W.F., and Fabisinski, L.F., III: Artificial Intelligence in Laboratory Medicine. Part IV: The Immunocompetence Profile, Clinical Forum, Dec., 27

### S

Sann, L., Bienvenu, J., Bienvenu, F., and Killingsworth, L.M.: The Acute-Phase Proteins in Neonatal Infection, Oct., 47

Scarry, R.L., Green, W.F., Fabis-inski, L.F., III, and Pribor, H.C.: Artificial Intelligence in Laboratory Medicine. Part IV: The Immunocompetence-Profile Clinical Forum, Dec. 27

Schlievert, P.M.: Microbiologic Markers in the Toxic Shock Syndrome, May, 38

Schumann, G.B., Schumann, J.L., and Schweitzer, S.: The

**Urine Sediment Examination:** A Coordinated Approach, Sept., 45

Schumann, J.L., Schumann, G.B., and Schweitzer, S.: The Urine Sediment Examination: A Coordinated Approach, Sept., 45

Schweitzer, S., Schumann, G.B., and Schumann, J.L.: The Urine Sediment Examination: A Coordinated Approach, Sept., 45

Seegmiller, J.E. and Gruber, H.E.: The Clinical and Laboratory Significance of Uric Acid Assay, Oct., 21

Shaughnessy, R., Jones, F.D., Davis, J.M., and Maas, J.: MHPG Excretion and Red-Cell Lithium Transport in Diagnostic Psychiatry, May,

Smith, T.F.: Chlamydial Infections: Clinical and Laboratory Features, Aug., 40

Snyder, J.R., Waters, J., (ed.): Effective Counseling, Supervisor's Corner, Feb., 56

Specter, S. and Friedman, H.: Verma, R.S. and Dosik, H.: Introduction: the Immunose-

rologic Diagnosis of Bacterial Infection, Nov., 13

Stevens, R.W.: Agglutination Tests in the Diagnosis of Bacterial Infection, Nov., 25

### T

Terasaki, P.I. and Arii, D.: The HLA Antigens: Histocompatibility Testing for Kidney Transplantation, Sept., 33

Thomas, V.L.: The Antibody Coated Bacteria Test: Uses and Findings, June, 39

Tilton, R.C.: The Role of CIE in Clinical Microbiology, Nov.,

Toffaletti, J.: Ionized Calcium Measurement: Analytical and Clinical Aspects, July, 31

Tseng, C.H.: Polarizing Microscopy of Fungi With the Red-I Plate, Dec., 33

Chromosome Banding: Tech-

niques and Prospects, March, 42

Waldman, A.A. and Pindyck, J.: Blood Donor Alanine Aminotransferase Levels: An Automated Screening System, June, 53

Wasserman, R.L. and Polin, R.A.: Monoclonal Antibodies: Progress and Promise, Oct., 33 Waters, J.H., (ed.), Snyder, J.R.: Effective Counseling, Supervisor's Corner, Feb., 56

Widen, R., Klein, T., and Friedman, H.: Newer Immunoassays in Clinical Bacteriology, Nov., 37

Widen, R., Friedman, H., and Klein, T.: Immunodiagnostic Assays for Legionellosis, Nov., 19

Yolken, R.H.: Monoclonal Antibodies in Microbiologic Immunoassay, Sept., 49

# INDEX TO SUBJECTS: LABORATORY MANAGEMENT, 1983

adenosine monophosphate; cyclic (cAMP); as indicator of parathyroid hormone secretion in hypercalcemic disease; March, 39

alanine aminotransferase; as indicator of hepatitis; automated screening for in blood donors; June, 53 in hepatitis non-A, non-B; Jan., 27

alpha-1-antitrypsin as acute-phase protein in diagnosis of neonatal infection; Oct., 49 deficiency of; automated screening for; Aug., 36

anemia; iron-deficiency; and microcytosis; Dec., 13

antibiotics aminoglycoside; metabolism in renal failure; June, 31 fluorescence polarization immunoassay for; July, 16

antibodies lgE; allergen-specific; tests for: Dec., 41 IgE; total; radioimmunosorbent test (RIST) for; Dec., 37 IgG; allergen-specific; tests for; Dec., 37

IgG and IgM; in pediatric infectious disease; tests for; Feb., 37

monoclonal; in microbiologic immunoassay; Sept., 49 monoclonal; in radioimmunodetection of tumors; July,20 monoclonal; laboratory applications of; Oct., 33 to Legionella pneumophila; tests for; Nov., 21

antibody

anti-carcinoembryonic antigen; in radioimmunodetection of tumors; July, 26 anti-human chorionic gonadotropin; in radioimmunodetection of tumors; July, 28 fluorescein-conjugated; in antibody-coated bacteria test; June, 40

IgA; as source of false-positive results in antibodycoated bacteria test; June.43 IgG; to hepatitis A virus; Jan., 19

IgM; in diagnosis of infantile C. trachomatis pneumonia; Aug., 49

IgM; to Chiamydia trachomatis; in pediatric patients; Feb., 37

IgM; to hepatitis A virus; Jan., 19

monoclonal; fluoresceinconjugated; for Chlamydia trachomatis in cytologic specimens; Aug., 48 to hepatitis B core antigen;

Jan. 22

to hepatitis B e-antigen; Jan., 22

antibody-coated-bacteria test; applications and interpretation; June, 39 antigen

carcinoembryonic (CEA); as marker in; medullary thyroid carcinoma; Aug., 29 carcinoemb yonic (CEA); in hepatitis non-A, non-B; Jan.,

colon-specific; in radioimmunodetection of tumors; July, 28

hepatitis B core (HBcAg); nature of; Jan., 20

hepatitis B e-; as component of hepatitis B core antigen; Jan., 20

hepatitis B surface (HBsAg); monoclonal antibodies to; Sept., 55

hepatitis B surface (HBsAg); nature of; Jan., 21 prostate-specific; April, 22

antigens bacterial; in meningitis: detection with counterimmunoelectrophoresis; Nov., 47 H and M; of fungal species; in exoantigen test; July, 37 human leukocyte (HLA); in histocompatibility testing; Sept., 33

human leukocyte (HLA); monoclonal antibodies to: Oct., 40

of Staphylococcus aureus; in toxic shock syndrome; May., 42 staphylococcal; tests for,

Nov., 48 streptococcal group B; identification with monoclonal antibodies; Oct., 35

tumor and cell-surface; investigation with monoclonal antibodies; Oct., 35 tumor; in radioimmunodetection; July, 20

antistreptolysin O latex particle agglutination test for; Nov., 27 antitrypsia

alpha-1; deficiency; automated screening for; Aug., 36 apolipoproteins

assays for; March, 19; April, 27 physicochemical characteristics of; March, 20

arsenic; intoxication; tests for; April, 13

ascorbic acid

metabolism of; May, 32 assav

colorimetric; for vitamin C; May, 36 colorometric; for uric acid in

gout: Oct., 22

counterimmunoelectrophoretic; for prostatic acid phos-

phatase; April, 20

electroimmuno-; for plasma apolipoproteins; March, 27 electrophoretic; for creatine kinase and lactate dehydrogenase isoenzymes in myocardial infarction; Feb., 23 enzymatic; for uric acid in gout; Oct., 23

enzyme immuno-; for chlamydial infection; Aug., 49 enxyme-linked; for hepatitis

B DNA; Jan., 23

enzyme-linked immunosorbent (ELISA); for anti-Legionella antibodies; Nov., 21 enzyme-linked immunosorbent (ELISA); for anti-teichoic acid antibodies in S. aureus infection Nov., 54

enzyme-linked immunosorbent (ELISA); for prostatic acid phosphatase; April, 22 enzyme-linked immunosorbent (ELISA); in pediatric viral infection; Feb., 37

enzyme-linked monoclonalantibody inhibition (ELMIA); for bacterial antigens; Oct., 35

fluorescence polarization; theory and application; July, 16

fluorescent antibody; in pediatric infectious disease; Feb., 37

fluorescent immuno-; for prostatic acid phosphatase; April, 20

immunoadsorbent; for prostatic acid phosphatase; April 21

immunodiffusion; for pathogenic fungi; July, 38

immunofluorescent; for Epstein-Barr virus in pediatric mononucleosis; Feb., 37

indirect fluorescent; for anti-Legionella antibody; Nov., 21 ionized calcium; with calcium-selective electrode; July, 31

isoelectric focusing; for S. aureus type C exotoxin in toxic shock syndrome; May, 39

latex agglutination; for H. influenzae; in pediatric patients; Feb., 36 latex particle agglutination;

for S. aureus protein A in pediatric infectious disease; Feb., 36

Limulus amoebocyte lyase; for *P. cepacia* endotoxin; Jan., 32

Limulus amoebocyte lyase; in diagnosis of chlamydial infection: Aug., 49

fection; Aug., 49 lithium ratio; in diagnosis of psychiatric illness; May, 23 Ouchterlony; for *S. aureus* type C exotoxin in toxic shock syndrome; May, 40 particle counting immuno; for total IgE in allergic dis-

ease; Dec., 41 radioimmuno-; for insulin;

May, 11 radioimmuno-; for parathyroid hormone; in differential diagnosis of hypercalcemic disease; March, 38

radioimmuno-; for plasma apolipoproteins; April, 27 radioimmuno-; for plasma free DNA in pulmonary embolism; Aug., 18

radioimmunoprecipitation; for allergen-specific IgG; Dec., 46

spectrophotometric; for vitamin C; May, 36

substrate labeled fluorescence immuno-; laboratory applications for; Oct., 13 ultraviolet; for uric acid in gout; Oct., 23

uric acid; in diagnosis and treatment of gout; Oct., 21 assays

automated; for alanine aminotransferase in blood donors; June, 55

enzymatic; for alpha-1-antitrypsin; Aug., 37

for acute-phase protein in neonatal infection; Oct., 50 immuno-; in diagnosis of infectious disease; monoclonal antibodies in; Sept., 50 immuno-; for prostatic acid phosphatase; April, 19

immunochemical; for alpha-1 antitrypsin; Aug., 37 immunochemical; for cre-

tine kinase and lactate dehydrogenase isoenzymes; March, 15

immunochemical; for plasma apolipoproteins; March, 25 immunochemical; for plasma apoliproteins; April, 34

Atlas of Blood Cells, Function and Pathology (Zucker-Franklin et al.); (Book review); April 46

automated testing; microbiologic; in pediatric infectious disease; Feb., 38

automation; in screening for alanine aminotransferase

levels in blood donors; June, 53

### В

bacteriuria; pediatric; testing for; Feb., 38

bands; chromosome; identification methods for; March, 42

Blastomyces dermatitidis; exoantigen test for; July, 36 blood

collection of; in therapeutic monitoring of antiarrhythmic drugs; Dec., 51

donors; automated screening for alanine aminotransferase levels; June, 53

blood-forming elements evolution of; Feb., 40

metabolism of; Feb., 40
Brucella abortus

agglutination tests for; Nov.,

### C

calcitonin

function in calcium metabolism; March, 32 in medullary thyroid carcinoma; Aug., 24, 26

calcium

factors affecting metabolism of; in hypercalcemic disease; March, 29

ionized; in differential diagnosis of hypercalcemic disease; March, 36

ionized; selective measurement of; July, 31 levels in bone disease; Feb.,

total; components of; March,

calcium infusion test; in diagnosis of medullary thyroid carcinoma; Aug., 26

hypercalcemia in; March, 33 metastatic to bone marrow; pathologic aspects; Feb., 48 prostate; antigen-marker assays for; April, 15

radioimmunodetection of; July, 19

carcinoma; medullary thyroid; diagnostic and clinical features of; Aug., 21

catecholamines; in psychiatric illness; May, 18 catecholamines; plasma levels of; in pheochromocytoma;

May, 11 cells

C-; of thyroid gland, in medullary thyroid carcinoma; Aug., 21 mast; role in allergic disease; Dec., 37

red blood; microcytic; significance of; Dec., 13 ceruloplasmin: blood levels of,

in neonatal infection; Oct., 50 cervicitis; caused by *Chlamydia* trachomatis; Aug., 41

Chlamydia species; identification with monoclonal antibodies; Oct., 35

Chlamydia trachomatis IgM antibody to; in pediatric infectious disease; Feb., 37 microbiologic features of; Aug., 40

chloride/phosphorus ratio; in computer profiling of parathyroid disease; June, 23

chloride; serum in differential diagnosis of hypercalcemic disease; March, 37

cholesterol; low-density lipid; as risk factor for atherosclerotic disease; March, 19

chromatography gas; in assay for 3-methoxy-4-hydroxyphenylglycol (MHPG) in psychiatric illness; May, 20

May, 20 gas; in diagnostic microbiology; April, 38

gas; in therapeutic monitoring of antiarrhythmic drugs; Dec., 51

gas-liquid; in toxicologic testing; Jan., 14

high-performance liquid (HPLC); in therapeutic monitoring of antiarrhythmic drugs; Dec., 51

high-performance liquid (HPLC); in uric acid assay; Oct., 25

high-performance liquid (HPLC); in toxicologic testing; Jan., 14

molecular-sieve; in apolipoprotein assay; March, 21 thin-layer; in toxicologic testing; Jan., 12

chromosome banding techniques in disease prediction and diagnosis; March, 42 coagulase; of Staphylococcus

aureus; serologic testing for; Nov., 48 Coccidioides immitis

exoantigen test for; July, 36 identification with polarizing microscopy; Dec., 23

Colour Atlas of Breast Cytopathology (Grubb); (Book review); March; 47

computers in blood-donor screening for alanine aminotransferase; June, 56 in profiling of immunocompetence; Dec., 28

in profiling of parathyroid disease; June, 21

cost-effectiveness; of urine sediment examination; Sept., 47

count; white blood cell (WBC); in neonatal infection; Oct., 49

creatine kinase (CK) isoenzymes; immunochemical assays for; March, 15 isoenzymes; in myocardial infarction; electrophoretic assays for; Feb., 23

Cryptococcus neoformans identification with polarizing microscopy; Dec., 23

culture blood; in pediatric infectious disease; Feb., 37 cell; for human leukocyte antigens (HLA); Sept., 36 cell: in diagnosis of chiamydial infection; Aug., 42 microbiologic; for S. aureus in toxic shock syndrome; May, 40 microbiologic; versus mono-

clonal antibodies in detection of microbial pathogens; Sept., 49

of fungal species; for exoantigen test; July, 38

cytogenetics: chromosome banding methods in; March,

cytology; in urine sediment examination; Sept., 46 cytomegalovirus; in pediatric patients; testing for; Feb., 37

d-aminolevulinic acid dehydrase; as indicator of lead poisoning; April, 14

depression; psychiatric; laboratory testing for; May, 17 diabetes mellitus; glycemic index in; Sept., 27

diarrhea; in medullary thyroid carcinoma; Aug., 29

digoxin fluorescence polarization immunoassay for; July, 16 therapeutic monitoring of;

factors in; June, 34 disease allergic; diagnostic methods

for; Dec., 37 as factor affecting drug metabolism; June, 31

cardiac; creatine kinase and lactate dehydrogenase isoenzyme patterns in; Feb.,

fungal; excantigen test in; July, 36 granulomatous; and hyper-

calcemia; March, 35 infectious: bacterial, immunoserologic testing for; Nov., 13, 19, 25, 37, 43, 48 infectious; gas chromatog-

raphy/mass spectrometry in diagnosis of; April, 38 infectious; pediatric; testing for; Feb., 35

neonatal infectious; acutephase protein levels in; Oct.,

parathyroid; computer profiling in; June, 21 DNA polymerase; in hepatitis B; assay for; Jan., 23

anticonvulsant; fluorescence polarization immunoassay for; July, 17 factors affecting plasma levels of; in therapeutic drug monitoring; June, 29 therapeutic monitoring of; hidden factors in; June, 29 toxicologic testing for; Jan.,

electrocardiography; versus creatine kinase and lactate dehydrogenase assays as an indicator of myocardial infarction; Feb., 31

electrode; calcium-ion selective; use; July, 32

electroimmunoassay; for plasma apolipoproteins; March,

electrophoresis

agarose gel; for creatine kinase and lactate dehydrogenase isoenzymes; in myocardial infarction; March, 15 counterimmuno-; for antiteichoic acid antibodies in

S. aureus infection; Nov., 54 counterimmuno-; for plasma free DNA in pulmonary embolism; Aug., 18

counterimmuno-; for prostatic acid phosphatase; April, 20 counterimmuno-; in pediatric infectious disease; Feb., 36 counterimmuno-; role in clinical microbiology; Nov., 43 for creatine kinase and lactate dehydrogenase isoenzymes; in myocardial infarc-

tion; Feb., 23 immuno-; for creatine kinase and lactate dehydrogenase isoenzymes in myocardial infarction; Feb., 23

polyacrylamide-gel; for quantitating plasma apolipoproteins; March, 23

polyacrylamide gel; for S. sureus antigens in toxic shock syndrome; May, 42 serum protein; in diagnosis of alpha-1-antitrypsin deficiency; Aug., 36

embolism; pulmonary; diagnostic testing for; Aug., 17 enzyme-linked immunosorbent

assay (ELISA) for pediatric viral infection; Feb., 37

for prostatic acid phosphatase; April, 22

enzyme-multiplied immunoassay technique (EMIT); in toxicologic testing; Jan., 13 enzymes; staphylococcal; sero-

logic testing for; Nov., 49 erythrocyte sedimentation rate; in diagnosis of neonatal in-

fection; Oct., 49 Escherichia coli; neonatal infection with; C-reactive protein levels in; Oct., 55

estriol; as indicator of fetal status in pregnancy; Feb., 17 estriol/creatinine ratio; as indicator of placental function in pregnancy Feb., 19

exotoxin; S. aureus type C; in toxic shock syndrome; May,

false-negative results in antibody-coated bacteria

test; June, 42 in testing for creatine kinase and lactate dehydrogenase isoenzymes in myocardial infarction; March; 15

false-positive results; in therapeutic drug monitoring; June, 34

fat; in bone marrow; relationship to bone and myeloid tissues; Feb., 40

fatty acids; microbial; gas chromatographic/mass spectrometric identification of; April, 41

fetal lung maturity; testing for; Feb., 17

fetal/placental function; assays for; Feb., 17

fluorometer; in substrate labeled fluorescent immunoassay; Oct., 13

Francisella tularensis; agglu- hypercalcemia tination tests for; Nov., 27

G

gas-chromatographic headspace analysis; in diagnostic microbiology; April, 42

gases; blood; values of in pulmonary embolism; Aug., 18 genetic factors in therapeutic drug monitoring; June, 30 genetics

of alpha-1-antitrypsin deficiency; Aug., 36

of human-leukocyte antigen (HLA) distribution; Sept., 33

glomerular filtration rate (GFR); and ascorbic acid metabolism; May, 22

glucose blood; food sources of; in diabetes mellitus; Sept., 29 plasma levels of; in insulinoma; May, 11

glycemic index; in diabetes mellitus; Sept., 27

gonorrhea; latex particle agglutination tests in diagnosis of; Nov., 29

gout; uric acid assay in diagnosis and treatment of; Oct., 21

H

Haemophilus influenzae latex-particle-agglutination test for; Nov., 29 tests for, in pediatric patients; Feb., 36

haptoglobin; as acute-phase protein in diagnosis of neonatal infection; Oct., 49

hepatitis types A, B, and non-A, non-B; laboratory diagnosis of; Jan.,

type B; recognition and history; Jan., 17 type B; vaccine for; Jan., 24 type B; viral DNA assay for; Jan., 23

non-A, non-B; prevention by screening for alanine aminotransferase in blood donors; June, 53

histaminase (diamine oxidase); as marker in medullary thyroid carcinoma; Aug., 29

Histoplasma capsulatum; excantigen test for; July, 36 hormones

monoclonal antibodies in assays for: Oct., 37 various; produced in medullary thyroid carcinoma; Aug., 29

human leukocyte antigens (HLA); in histocompatibility testing; Sept., 33

as a diagnostic factor in disease; March, 29 differential diagnosis of; March, 29 in multiple myeloma; Feb., 51 physiologic; March, 33 source of; in different disease states; March, 29

hypercalciuria; in hyperparathyroidism; March, 37

hyperparathyroidism hypercalcemia in; March, 35 in medullary thyroid carcinoma; Aug., 22 ionized and total calcium

levels in; July, 35

hyperplasia; C-cell; preceding medullary thyroid carcinoma; Aug., 22

hypoglycemia; in insulinoma;

May, 11

hypoxanthine guanine phosphoribosyl transferase; deficiency of; and gout; Oct., 26 in hybridoma technology; Oct., 34

immunity; cellular; to Legionella species; tests for; Nov., 22 immunoassay

enzyme; for rotavirus; monocional antibodies in; Sept., 50 enzyme-multiplied (EMIT); in therapeutic monitoring of antiarrhythmic drugs; Dec., 51 fluorescent; for prostatic acid phosphatase; April, 20 fluorescent; indirect; for anti-Legionella antibodies; Nov.,

substrate labeled fluorescence; laboratory applications for; Oct., 13

immunoassays; enzyme-, enzyme-linked, flourescent, and radio-; in clinical bacteriology; Nov., 37-41

immunocompetence; automated profiling of; Dec., 27

immunodiffusion in exoantigen test for pathogenic fungi; July, 38 radial; assay for alpha-1-anti-

trypsin; Aug., 37

immunoglobulins IgG, IgM, and IgA; in automated profiling of immunocompetence; Dec., 27 IgM; in neontal infection; Oct., 49

infection bacterial; immunoserologic diagnosis of; Nov., 13 chlamydial; diagnostic test-

ing for; Aug., 40 neonatal; acute-phase proteins in; Oct., 47

nosocomial; caused by P. cepacia; Jan., 29 pediatric; testing for; Feb., 35

staphylococcal; serodiagnostic aspects; Nov., 48 urinary tract; antibody-coated bacteria test for; June, 39 urinary tract; pediatric; test-

ing for; Feb., 38 viral; in pediatric patients; tests for; Feb., 37

insulin; plasma levels of; in insulinoma; May, 12

insulinoma; laboratory testing for; May, 11 Interpretation of Electropho-

retic Patterns of Proteins and

Isoenzymes; A Clinical Pathological Guide (Wolff et al.); (Book review); April, 46

intoxication; vitamin D; as source of hypercalcemia; March, 36

isoelectric focusing for quantitating plasma apolipoproteins; March, 24 for S. aureus type-C exotoxin in toxic shock syndrome; May, 39

isoniazid; factors in therapeutic monitoring of; June, 32

Laboratory Medicine: Hematol-June, 62

laboratory; personnel; effective counseling for; Feb., 56

lactate dehydrogenase and cell turnover in hematologic disease; Feb., 51 isoenzymes; immunochemical assays for; March, 15 isoenzymes; in myocardial assays for; Feb., 23 serum levels; in pulmonary embolism; Aug., 18

offerty index; in computer pro-filing of parathyroid disease; microscope; fluorescent; in Lafferty index; in computer pro-June, 21

lead; intoxication; tests for; April, 13

lecithin/sphingomyelin ratio; as indicator of fetal lung maturity; Feb., 17

Legionella pneumophila gas chromatographic/mass spectrometric identification of; April, 41 immunoserologic tests for;

Nov., 19 leukemia; chronic granulocy-

tic; myeloid aspects of; Feb., 46

lidocaine; therapeutic monitoring methods for; Dec., 51

lipoproteins; plasma; and cholesterol; in atherosclerotic disease; March, 19

lithium ratio; in diagnosis of depressive illness; May, 23 liver; histopathology of; in hepatitis; Jan., 20, 23, 27

Loboa loboi; identification with polarizing microscopy; Dec., 33

lymphocytes; B isolation of; in testing for human leukocyte antigens; Sept., 38 subsets; ratios of; in acquired immune deficiency syndrome; Dec., 27 T; subsets; identification with monoclonal antibodies;

Oct., 43

lymphogranulorna venereum; C. trachomatis sources of; Aug., 41

marrow; relationship to bone and fat; pathophysiology of; Feb., 40

mean corpuscular volume (MCV); in microcytosis; Nov., 13

meningitis

bacterial; counterimmunoelectrophoresis in diagnosis of; Nov., 47 bacterial; pediatric; tests for;

Feb., 36 ogy (Miale); (Book review); mercury intoxication; tests for;

April, 13 metal poisoning; tests for;

April, 13 3-methoxy-4-hydroxyphenylglycol (MHPG); as marker of psychiatric disorder; May, 11 microbiology; gas chromatography/mass spectrometry in;

April, 38 infarction; electrophoretic microcytosis; as indicator of disease; Dec., 13

microcytotoxicity test; for human leukocyte antigens

chromosome banding studies; March, 44

microscopy

electron; in diagnosis of medullary thyroid carcinoma; Aug., 24

fluorescence; in antibodycoated bacteria test; June, 40 for urate crystals in gout; Oct., 22

in diagnosis of C. trachomatis infection; Aug., 42 in urine sediment examina-

tion; Sept., 46 polarizing; for the identifi-

cation of pathogenic fungi; Dec., 33

mononucleosis; infectious; in pediatric patients; testing for; Feb., 37 multiple endocrine neoplasia;

association with medullary thyroid carcinoma; Aug., 22 Mycobacterium tuberculosis;

gas chromatographic/mass spectrometric identification of; April, 42

Mycoplasma species; identification with monoclonal antibodies; Oct., 35

myeloid tissues; evolution of; Feb., 41

myeloma multiple; bone pathology in; Feb., 51 multiple; hypercalcemia in; March, 34

myocardial infarction

levels in; Feb., 23

creatine kinase and lactate dehydrogenase isoenzymes in; immunochemical assays for; March, 15 creatine kinase and lactate dehydrogenase isoenzyme

N-acetylprocainamide; in therapeutic monitoring for procainamide; Dec., 52

N-alpha-benzoyl-D,L-argininep-nitroanilide (BAPNA); as substrate in enzymatic assay for alpha-1-antitrypsin; Aug., 37

Neisseria gonorrhoeae; tests for; in pediatric patients;

Feb., 36

Neisseria species; gas chromatographic/mass spectrometric identification of April,

neonatal infection; acutephase proteins in diagnosis of; Oct., 47

neuromas; mucosal; association with medullary thyroid carcinoma; Aug., 22

nomogram; Dettli; in therapeutic drug monitoring; June, 31

norepinephrine; and normetanephrine; in depressive illness; May, 18

orosomucoid; as acute-phase protein in diagnosis of neonatal infection; Oct., 49 osteopetrosis; bone pathology

in: Feb., 48 osteoporosis; in malignant and nonmalignant bone disease; Feb., 48

pancreatitis; ionized calclum measurement in; July

parathyroid hormone effects on calcium metabolism; March, 32 in computer profiling of

parathyroid disease; June,

pentagastrin; injection; in diagnosis of medullary thyroid carcinoma; Aug., 26

personnel; laboratory; effective counseling methods for; Feb., 56

pheochromocytoma associated with medullary thyroid carcinoma; Aug., 22 laboratory testing for; May, 11

phosphatase

alkaline; in differential diagnosis of hypercalcemic disease; March, 39 prostatic acid; in diagnosis of prostate cancer; assay for; April, 19

prostatic acid; in radioimmumunodetection of tumors;

July, 28

phosphate; renal tubular; resorption of; in hypercalcemic disease; March, 38 phosphorus; serum; in differen-

tial diagnosis of hypercalcemic disease; March, 36 Plasmodium species; monoclo-

nal antibodies in study of; Oct., 36 Pneumocystis carinii pneumo-

nia; pediatric; testing for; Feb., 36

pneumonia; pediatric infectious; testing for; Feb., 36 polypharmacy; as factor in therapeutic drug monitoring;

June, 32

pregnancy as factor in therapeutic drug monitoring; June, 32 high-risk; fetal testing in; Feb., 17

procainamide

factors in therapeutic monitoring of; June, 33 therapeutic monitoring methods for; Dec., 51

Procedures for the Coagulation Laboratory (Triplett and Harms); (Book review); April, 46

profile; diagnostic; automated; of immunocomepetence;

propranolol; therapeutic monitoring methods for; Dec., 51 protein

staphylococcal type A; in solid-phase radioimmunoassay for allergen-specific IgG; Dec., 46

C-reactive; in bacterial infection; latex-particle-agglutination test for; Nov., 25 C-reactive; in diagnosis of

neonatal infection; Oct., 49 proteins; acute-phase; in neonatal infection; Oct., 47

protoporphyrin

free erythrocyte; in iron deficiency anemia; Dec., 13 zinc; in lead poisoning; April, 14

pseudohyperparathyroidism; in cancer; March, 34 Pseudomonas aeruginosa; as source of false-negative results in antibody-coated bacteria test; June, 43

Pseudomonas cepacia; culture and laboratory identification: Jan., 29

pulmonarry embolism; diagnostic testing for; Aug., 17

a

quality assurance; in urine sedment examination; Sept., 46

radial immunodiffusion; as assay method for plasma apolipoproteins; March, 25 radiommunossay

for calcitonin; in diagnosis of medullary thyroid carcino-

ma; Aug., 27 for estriol in pregnancy; Feb., 17

for IgG and IgM antibodies to S. aureus peptidoglycan; Nov., 52

for IgG antibody to hepatitis

A virus; Jan., 19 for insulin; in insulinoma;

May, 11 for parathyroid hormone; in differential diagnosis of hypercalcemic disease: March.

for plasma apolipoproteins; April, 27

for plasma free DNA in pulmonary embolism; Aug., 18 in diagnosis of bacterial infection; Nov., 38

solid-phase (SPRIA); for allergen-specific IgG; Dec., 46

radioimmunoassays; for microbial antigens; monoclonal antibodies in; Sept., 50

radioimmunodetection; of tumors; theory and application; July, 19

Rhinosporidium seeberi; identification; with polarizing microscopy; and Red-I filter Dec., 33

salicylates; interference with methotrexate; in therapeutic drug monitoring; June, 32 sarcoidosis; hypercalcemia in;

March, 35 screening

automated; for alanine amino transferase levels in blood donors; June, 53 automated; for alpha-1-antitrypsin deficiency; Aug., 36

selected ion monitoring; in gas chromatographic/mass spectrometric identification of microbial pathogens; April,

sensitivity; antimicrobial; of S. aureus strains in toxic shock syndrome; May, 41

Significance of Medical Microbiology in the Care of Patients (Lorian); (Book review); June, 62

sodium-potassium pump; and lithium transport; in diagnosis of psychiatric illness; May, 23

spectrometry; mass; with gas chromatography; in diagnostic microbiology; April, 38

spectroscopy atomic absorption; in lithium test ratio assay in psychiatric illness; May, 29

fluorescence; in therapeutic monitoring of antiarrhythmic drugs; Dec., 51

Sporothrix schenckii; exoantigen test for: July, 36

stain

Grimelius argyrophil; in histopathologic diagnosis of medullary thryroid carcinoma; Aug., 24

hematoxylin-eosin; in fungal identification with polarizing microscope; Dec., 33

stains; cytologic; for Chlamydia trachomatis; Aug., 42 Staphylococcus aureus; as agent of toxic shock syndrome; identification of; May, 38 infection; serodiagnostic as-

pects; Nov., 48 rapid agglutination tests for; Nov., 31

tests for; in pediatric patients; Feb., 36

streptococci

beta-hemolytic: identification with counterimmunoelectrophoresis; Nov., 47 group B; latex particle agglutination test for; Nov., 29

Streptococcus pneumoniae; tests for; in pediatric patients; Feb., 36

Streptococcus species; gas chromatrographic/mass spectrometric identification of; April, 41

syndrome; acquired immune deficiency (AIDS); immunocompetence profile in; Dec.,

acquired immune deficiency (AIDS); monoclonal antibodies in diagnosis of Oct., 43 "fragile X"; chromosome abnormality in; March, 43 Lesch-Nyhan; and gout; Oct.,

milk-alkali; and hypercalcemia; March 35 Prader-Willi; chromosome abnormality in; March, 43 Reiter's: C. trachomatis as possible source of; Aug., 41 Sipple; in medullary thyroid carcinoma; Aug., 21 toxic shock; microbiclogic markers of; May, 38 Zollinger-Ellison; as manifestation of hyperparathyroidism; March, 38 syphilis; agglutination tests in diagnosis of; Nov., 27

antibody-coated-bacteria; applications and interpretation; June, 39 calcium-infusion; in diagnosis of medullary thyroid carcinoma; Aug., 26 calcium pentagastrin; in diagnosis of medullary thyroid carcinoma; Aug., 26 CaNa<sub>2</sub>-EDTA; for lead nephropathy; April, 13 complement-fixation; for chlamydial infection; Aug.,

conjugated bile acid (CBA); in hepatitis non-A, non-B; Jan., 26

dexamethasone suppression; in diagnosis of psychiatric illness; May, 24 exoantigen; for dimorphic

fungi; July, 36 FTA-ABS; for syphilis; com-

parison with rapid plasma reagin test; Nov., 27 immunofluorescent; for chlamydial infection; Aug., 48 lymphocyte blastogenic transformation; for cellular immunity to Legionella

species; Nov., 22 microcytotoxicity; in tissue typing for human leukocyte antigens (HLA); Sept., 38 plasma free DNA; in pulmo-

nary embolism; Aug., 18 radioallergosorbent (RAST); for allergen-specific IgE in allergic disease; Dec., 41 radioimmunosorbent (RIST); for total IgE in allergic disease; Dec., 41

rapid plasma reagin (RPR); for syphilis; Nov., 27 Reinsch; for arsenic and mer-

cury intoxication; April, 15 24-hour urinary urate; in management of gout; Oct., 21

agglutination; in diagnosis

of bacterial infection; Nov.,

diagnostic; for hepatitis A, hepatitis B, hepatitis non-A, non-B; Jan., 18

for metal poisoning; April, 13 for pediatric infectious disease; Feb., 35

histocompatibility; mono-clonal antibodies in; Oct., 35 nonspecific diagnostic; for neonatal infection; Oct., 48 toxicologic; for common

drugs; Jan., 11 toxoplasmosis, rubella, cytomegalovirus, herpes virus (TORCH) series; in pediatric patients; Feb., 37

thalassemia; and iron deficiency anemia; differential diagnosis; Dec., 14

thalassemias; myeloid aspects of; Feb., 51

therapeutic drug monitoring; hidden factors in; June, 29 thiazide diuretics; as sources of hypercalcemia; March, 35

thyroxine (T<sub>4</sub>)

and triiodothyronine (T,); fluorescence polarization immunoassay for; July, 17 and triiodothyronine (Ta); up-

take; measurement in differential diagnosis of hypercalcemic disease; March, 39

toxic shock syndrome; microbiologic markers of; May, 38 toxins; staphylococcal; as factors of infection; Nov., 50

transaminase; glutamic oxaloacetic; serum levels in pulmonary embolism; Aug., 18

transfusion; blood; and transmission of hepatitis non-A, non-B; Jan., 25

Treponema pallidum; serologic tests for; Nov., 27

trypsin; in enzymatic assay for alpha-1-antitrypsin; Aug., 37,

typing

blood and tissue; monoclonal antibodies in; Oct., 38 tissue; for kidney transplantation; with human leukocyte antigens (HLA); Sept., 33

urethritis; caused by Chlamydia trachomatis; Aug., 41

uric acid; assay for; in diagnosis and treatment of gout; Oct., 21

estriol levels in; for monitoring fetal/placental function in pregnancy; Feb., 19 sample collection; for antibody-coated bacteria test; June, 40

sediment; examination of; coordinated approach to; Sept., 45

tion; Jan., 18

identification of with mono-

typing of; monoclonal anti-

C; metabolism and assay:

D; in pathophysiology of

D; metabolism and effect on

calcium metabolism; March,

in diagnosis of lead poison-

voltammetry; anodic-stripping;

clonal antibodies; Oct., 34

bodies in; Sept., 51

viruses

vitamin

May, 31

bone; Feb., 40

ing; April, 14

Western blotting technique; for S. aureus antigens in toxic shock syndrome; May, 42

virus

Epstein-Barr; in pediatric mononucleosis; testing for; Feb., 37

hepatitis A and B; Jan., 18 hepatitis; characteristics and antigens of, and identifica-

## CLASSIFIED ADVERTISING

MAIL: CLASSIFIED ADV. DEPT LABORATORY MANAGEMENT 475 Park Ave. So., New York, NY 10016 or call Phyllis Jasel (212) 725-2300

NORTH CAROLINA: CLINICAL IMMUNOHEMATOLOGY INSTRUCTOR—ASCP or equivalent certification

Master's degree preferred; 1 to 3 years clinical teaching experience. Responsible for teaching in at least one Medical Technology discipline, assisting in other instructional, advising, and development responsibilities. Rank and salary negotiable. Forward letter of application, current resume, transcripts and three (3) letters of recommendation to:

Dr. Arnold Lockett, Vice-Chancellor for Academic Affairs, Winston-Salem State University, Winsten-Salem, North

### DIAMOND SCRIBER

MEDICAL LABS find many uses for diamond scribers to label glass slides, glassware and hard plastics. \$3.25 ea. (add 16¢ in N.J.)

VICTORY DIAMOND TOOL CO., INC. BOX 274, E. Hanover, NJ 07936 201-887-2221

FOR SALE

**SEARLE ANALYTIC & PACKARD** BETA AND GAMMA COUNTING SYSTEMS LONG ISLAND SCIENTIFIC

Box 476 Port Jefferson, NY 11777 (516) 981-6800 Rental & Lease Plans Available

THE ALL-NEW PBM **DUAL-VIEW MICROSCOPE TABLE!** 

Designed to take years of hard use, these sturdy tables feature all heavy duty reinforced plywood construction with wear-resistant plastic laminate tops, heavy duty locking casters, "push me-pull me" drawers that open or close from either side and an electrical outlet

> **PBM SERVICE COMPANY** (617) 232-8738

Circle No. 119 on Inquiry Card

COLEMAN LABORATORIES CORP. helps you conserve capital with quality reconditioned laboratory and hospital equipment. FOR SALE OR LEASE

ASTRA 8, very good cond
CORNING 175 Blood Gas, refurb \$4,999
GILFORD 203 SYSTEM \$7,995
SMA II, very good cond
DUPONT ACA-II-60, on service contract \$14,995
SMA's, most types 12/60, 6/60, 1 yr. warranty . Inquire
GAMMA BETA COUNTERS, all types Inquire
COULTER S, S Senior, S Plus, Sn, Fn, ZBI, Zl Inquire
AMSCO & CASTLE STERILIZERS Inquire
SPECTROPHOTOMETERS, all types Inquire
FLAME PHOTOMETERS ATOMIC ABSORPT Inquire
ULTRACENTIFUGES Prep & Analytic Inquire
ELECTROPHORESIS, Centrifuges, Scopes Inquire
GAS & LIQUID CHROMATOGRAPHS Inquire
MICROTOMES, Cryostat, Knile Sharpeners Inquire
CHEMISTRY ANALYZERS, all types Inquire
ASK FOR LATEST QUOTE BEFORE YOU BUY

nstruments subject to prior sale

COLEMAN LABORATORIES CORP. 958 Washington Rd., Pittsburgh, PA 15228

TELEPHONE (412) 343-5055 • TELEX 812324 TAS/PGH

**EQUIP TO SELL** Call us for a good offer

American Diagnostics, Inc.

SMAC & SMA Replacement parts, consumables, and repair services. Refurbished instruments. Call for quote. Economical Pricing! Contact:

107 Prespect Place, Hillsdale, NJ 07642 Call COLLECT: (201) 358-1001 DEALER INQUIRIES INVITED

### **REISS TECHNICAL SERVICES ASTRAS & SMA SYSTEMS Bought & Sold**

- · We specialize in remanufacturing Beckman Astras and Technicon SMA Systems.
- · We supply consumables, replacement parts, reagents and service and maintenance contracts. . Top dollar paid for used Astra's, SMA's & AAII's

Reiss Technical Services P.O. Box 791 Westfield, NJ 07090 TEL: (201) 381-1300



